You are here

Pfizer R&D Spending Increases To Accelerate Blockbuster Drug Approvals

Drugmaker Aiming for 25–30 New Drugs by 2022

Pfizer Inc. plans to increase research and development spending for the remainder of the year in an ambitious plan to accelerate the delivery of potential blockbuster treatments to market.

The drugmaker raised projections for spending on research to $7.7 billion to $8.1 billion from $7.4 billion and $7.9 billion previously. With a 26% increase in net income, Pfizer expects between 25 and 30 drugs from its pipeline to be approved through 2022.

Sales of Pfizer’s off-patent brands and generic drugs fell in the last quarter, and sales of Lyrica, its fibromyalgia drug, dipped 3% to $1.2 billion. Pfizer also lost trademark exclusivity for Viagra, and sales for that drug fell 47% over the past year to $185 million.

Source: The Wall Street Journal, July 31, 2018

More Headlines

COMPASS Trial Shows 24% Reduction in Major CV Events
Only 18.7% of Patients Treated Had Uveitis Recurrence
Protein Organizes and Stores DNA for B Cells in Methodical Fashion
Patients’ Bodies Most Common Source of Hospital-Acquired Bloodstream Infections
Growing opioid crisis fueling suicide increase according to study
Vaccine Prevents Some Cancers, Diseases Caused by 9 HPV Types
In Future, Providers May Screen for APOE4 Before Treatment 
MIT Professor Working to Produce Thousands of Drugs on Demand
Agency Scrutinizes Attempts to Block Generics